Seeking Alpha

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains...

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains 14.6% after reporting Q3 revenue of $93M and EPS of $0.40; while the latter missed by $0.33, the former beat by $2.2M, and investors appear reassured by positive comments regarding market acceptance of the company's Ampyra MS drug, made in partnership with ELN.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector